Do Drugs Given Expedited Approval Have More Safety Risks? GAO Says FDA Can't Tell
This article was originally published in The Pink Sheet Daily
Executive Summary
Findings could give pharmacovigilance prominence alongside 'breakthrough' and other speed mechanisms in legislative debate on agency reform.